Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
BACKGROUND: This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point. METHODS: Chemotherapy-naïve patients with histologi...
Main Authors: | O'Brien, M, Gaafar, R, Popat, S, Grossi, F, Price, A, Talbot, D, Cufer, T, Ottensmeier, C, Danson, S, Pallis, A, Hasan, B, Van Meerbeeck, J, Baas, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2013
|
Similar Items
-
European guidelines for the management of malignant pleural mesothelioma
by: Eric van Thiel, et al.
Published: (2011-10-01) -
Phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma
by: Fennell, D, et al.
Published: (2018) -
Pleural mesothelioma metastasis of the scalp
by: Tugcem Bicak, et al.
Published: (2024-02-01) -
Pleural Mesothelioma in the Era of Immunotherapy
by: Mathieu Chevallier, et al.
Published: (2023-07-01) -
Extrathoracic Metastases in Pleural Mesothelioma
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-09-01)